Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HLCS | P50747 | 6/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | ABL1 | P00519 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | IDE | P14735 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | CA12 | O43570 | 7/20 | 0.47 |
| ▸ | CA1 | P00915 | 7/20 | 0.47 |
| ▸ | CA2 | P00918 | 7/20 | 0.47 |
| ▸ | CA9 | Q16790 | 7/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12050328 | 0.98 | HLCS (0.73) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL29341874 | 0.98 | HLCS (0.73) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL10140308 | 0.84 | HLCS (0.72) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL16141168 | 0.84 | HLCS (0.97) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL10038443 | 0.84 | HLCS (1.00) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL423924 | 0.84 | HLCS (1.00) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL16664701 | 0.84 | HLCS (0.72) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL12990072 | 0.84 | HLCS (0.72) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL21769329 | 0.84 | HLCS (1.00) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL19278027 | 0.84 | HLCS (0.72) | HLCSTDP1MEN1ABL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030864-B2 | Small molecule anticancer agents, combinations and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-07-09 | — | — | US | disclosed |
| US-20210147379-A1 | NOVEL SMALL MOLECULE ANTICANCER AGENTS, COMBINATIONS AND USES THEREOF | University of Florda Research Foundation,Incorporated (US) | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147379-A1 | NOVEL SMALL MOLECULE ANTICANCER AGENTS, COMBINATIONS AND USES THEREOF | MKI67, TP53, PLK1 | HLCS 1943/4885TDP1 1148/4885MEN1 2251/4885 |
| US-12030864-B2 | Small molecule anticancer agents, combinations and uses thereof | MKI67, TP53, PCNA | HLCS 1638/4885TDP1 967/4885MEN1 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.